AU2020249493B2 - Combinations of iadademstat for cancer therapy - Google Patents

Combinations of iadademstat for cancer therapy

Info

Publication number
AU2020249493B2
AU2020249493B2 AU2020249493A AU2020249493A AU2020249493B2 AU 2020249493 B2 AU2020249493 B2 AU 2020249493B2 AU 2020249493 A AU2020249493 A AU 2020249493A AU 2020249493 A AU2020249493 A AU 2020249493A AU 2020249493 B2 AU2020249493 B2 AU 2020249493B2
Authority
AU
Australia
Prior art keywords
inhibitor
cancer
iadademstat
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020249493A
Other languages
English (en)
Other versions
AU2020249493A1 (en
Inventor
Filippo CICERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oryzon Genomics SA
Original Assignee
Oryzon Genomics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics SA filed Critical Oryzon Genomics SA
Publication of AU2020249493A1 publication Critical patent/AU2020249493A1/en
Application granted granted Critical
Publication of AU2020249493B2 publication Critical patent/AU2020249493B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020249493A 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy Active AU2020249493B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
EP19382206.1 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Publications (2)

Publication Number Publication Date
AU2020249493A1 AU2020249493A1 (en) 2021-09-16
AU2020249493B2 true AU2020249493B2 (en) 2025-08-28

Family

ID=66175363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020249493A Active AU2020249493B2 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC10.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC10.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210142614A (cg-RX-API-DMAC10.html)
CN (2) CN113573702A (cg-RX-API-DMAC10.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC10.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC10.html)
IL (1) IL286353A (cg-RX-API-DMAC10.html)
MX (1) MX2021011610A (cg-RX-API-DMAC10.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC10.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083138A1 (en) * 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018083138A1 (en) * 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANQIANG SHENG ET AL: "LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade", CELL, vol. 174, no. 3, 1 July 2018, pages 549-563 *

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
JP7824627B2 (ja) 2026-03-05
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
IL286353A (en) 2021-10-31
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
JP2026077769A (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
JP2019517549A5 (cg-RX-API-DMAC10.html)
RU2006120950A (ru) Антитело к cd40: препарат и способы
CN108295063A (zh) 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂)
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
TW201914592A (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
CA2984316A1 (en) Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
JP2021514975A (ja) サイクリン依存性キナーゼ阻害剤およびbet−ブロモドメイン阻害剤の組合せ
EP3463453A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
EP2841099A1 (en) Combination of cd37 antibodies with bendamustine
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
EP3914257B1 (en) Combination of a bcl-2/bcl-xl inhibitor with osimertinib
RU2833564C2 (ru) Комбинации иададемстата для лечения рака
JP2017515843A (ja) 抗egfr治療薬の投与量および投与
JP2023531090A5 (cg-RX-API-DMAC10.html)
CN116113411A (zh) 用于治疗软组织肉瘤的联用药物
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
TW202045175A (zh) Sumo-活化酶抑制劑及檢查點抑制劑之投與
AU2020278733A1 (en) Quinoline derivatives for treatment of head and neck cancer
JP7504106B2 (ja) がんの処置のための組合せ物
WO2023204259A1 (ja) がんの治療又は予防用医薬
CN100553634C (zh) 用于治疗多发性骨髓瘤的埃坡霉素衍生物
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)